APOL1-associated kidney disease: modulators of the genotype-phenotype relationship
- 6 March 2025
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Nephrology and Hypertension
- Vol. 34 (3) , 191-198
Abstract
Purpose of review: Apolipoprotein-L1 (APOL1) G1 and G2 risk variants, found in people of recent west sub-Saharan African ancestry, dramatically increase the likelihood of kidney disease, yet the incomplete penetrance an diverse clinical manifestations underscore the need to understand the molecular and environmental factors that modulate APOL1-mediated toxicity. Recent findings: Recent studies confirm that risk variants exert a toxic gain-of-function effect, exacerbated by inflammatory triggers such as HIV infection and COVID-19. Epigenetic mechanisms and microRNA pathways further modulate APOL1 expression, influencing disease penetrance. Multiple models have clarified how subcellular localization, signal peptide processing, and interactions with the endoplasmic reticulum may contribute to pathogenesis. Therapeutic advances include inhibitors targeting APOL1 ion channel activity and strategies that block key inflammatory signaling pathways. Summary: These findings highlight a multifaceted disease process driven by both the intrinsic toxic potential of APOL1 variants and numerous extrinsic triggers. Understanding this complex interplay will be pivotal for risk stratification and the development of precision therapies, potentially improving outcomes for populations disproportionately affected by APOL1-associated kidney disease.Keywords
This publication has 90 references indexed in Scilit:
- The Janus-faced functions of Apolipoproteins L in membrane dynamicsCellular and Molecular Life Sciences, 2024
- Apolipoproteins L1 and L3 control mitochondrial membrane dynamicsCell Reports, 2023
- Apolipoprotein L1 (APOL1) cation current in HEK-293 cells and in human podocytesPflügers Archiv - European Journal of Physiology, 2022
- APOL1 Risk Variants, Acute Kidney Injury, and Death in Participants With African Ancestry Hospitalized With COVID-19 From the Million Veteran ProgramJAMA Internal Medicine, 2022
- SNPs at 3′UTR of APOL1 and miR-6741-3p target sites associated with kidney diseases more susceptible to SARS-COV-2 infection: in silco and in vitro studiesMammalian Genome, 2021
- All You Ever Wanted to Know About APOL1 and TLFs and Did Not Dare Ask2020
- APOL1 C-Terminal Variants May Trigger Kidney Disease through Interference with APOL3 Control of ActomyosinCell Reports, 2020
- End‐Stage Renal Disease in African Americans With Lupus Nephritis Is Associated With APOL1Arthritis & Rheumatology, 2013
- Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 geneHuman Genetics, 2010
- The Human Apolipoprotein L Gene Cluster: Identification, Classification, and Sites of DistributionGenomics, 2001